Previously, we identified several TSGs in NPC and ESCC that are either encoding ECM proteins (FBLN2 [21] and LTBP2 [22, 34, 35]) or proteases involved in ECM remodelling (ADAMTS9 [36, 37] and MMP19 [38]). The re-expression of these TSGs was reported to suppress NPC and/or ESCC cell migration, invasiveness, angiogenesis, and in vivo tumor growth [21, 22, 34–36]. The gene discussed is LTBP2; the disease is esophageal squamous cell carcinoma.